Spitfire List Web site and blog of anti-fascist researcher and radio personality Dave Emory.

Heads We Win, Tails You Lose: The Fascist Philosophy Behind Private Equity’s Leveraged Buyout of Everything

It’s been the same head­line for months now:
* April of 2020: Amer­i­can bil­lion­aires have got­ten $280 bil­lion rich­er since the start of the COVID-19 pan­dem­ic
* May of 2020: Amer­i­can bil­lion­aires got $434 rich­er dur­ing the pan­dem­ic
* August of 2020: Amer­i­can bil­lion­aires got $637 rich­er dur­ing the pan­dem­ic
* Sep­tem­ber of 2020: U.S. bil­lion­aires got $845 bil­lion rich­er since the start of the pan­dem­ic/Wealth of US bil­lion­aires ris­es by near­ly a third dur­ing pan­dem­ic
* Octo­ber of 2020: US bil­lion­aires saw their net worth rise by almost $1 tril­lion between March and Octo­ber — Jeff Bezos remains the rich­est, a study says.

From near­ly the start of the COVID-19 pan­dem­ic it’s been clear that the pub­lic health dis­as­ter was­n’t a dis­as­ter for every­one, with the wealth­i­est indi­vid­u­als being not only large­ly insu­lat­ed from the eco­nom­ic lock­down but in many cas­es well posi­tioned to prof­it from it. The pan­dem­ic was turn­ing into a giant upward trans­fer of wealth. And as we’re going to see, giant upward trans­fers of wealth are essen­tial­ly what the pri­vate equi­ty indus­try is all about. The rise of ‘sup­ply-side’ eco­nom­ics in the 1980s coin­cid­ed with the rise of pri­vate equi­ty and that’s no coin­ci­dence. The phi­los­o­phy behind the pri­vate equi­ty move­ment is the phi­los­o­phy of sup­ply-side eco­nom­ics. An anti-New Deal phi­los­o­phy, where ruth­less­ness is a virtue, that fueled a 40 year giant fas­cist lever­aged buy­out of soci­ety.

FTR #1139 The Anthrax Attacks, the Invasion of Iraq and Expansion of Biological Warfare Capabilities

As the title indi­cates, this pro­gram presents polit­i­cal and his­tor­i­cal foun­da­tion for the expo­nen­tial expan­sion of Amer­i­can bio­log­i­cal war­fare infra­struc­ture fol­low­ing the 2001 anthrax attacks.

Impor­tant back­ground infor­ma­tion comes from the Whit­ney Webb arti­cle about DARPA spend­ing on bat-borne coro­n­avirus­es.

The Broad­cast­ing Board of Governors–a CIA “derivative”–and The Wash­ing­ton Times (owned by the Uni­fi­ca­tion Church) helped devel­op dis­in­for­ma­tion about SARS CoV‑2 com­ing from a Chi­nese Bio­log­i­cal War­fare lab. Both were instru­men­tal in hyp­ing the anthrax attacks as authored by Sad­dam Hus­sein, as well. The Wash­ing­ton Times also pre­sent­ed infor­ma­tion float­ed by Steven Hat­fill that fore­shad­owed sub­se­quent charges that Sad­dam Hus­sein was devel­op­ing bioweapons and was behind the 2001 anthrax attacks.

In addi­tion, the Project For a New Amer­i­can Cen­tu­ry was advanc­ing an agen­da in which genet­i­cal­ly-engi­neered bio­log­i­cal war­fare tech­nol­o­gy as essen­tial to con­tin­ued Amer­i­can glob­al dom­i­nance.

As will be seen below, a key func­tionary in the PNAC milieu was for­mer Sec­re­tary of Defense Don­ald Rums­feld, for­mer chair­man of the board of Gilead Sci­ences.

In FTR #‘s 1135, 1136 and 1137, we relied heav­i­ly on the Kris New­by’s Bit­ten: The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons. In that book, Ms. New­by net­worked with a group of expe­ri­enced, Cold War bio­log­i­cal war­fare pro­fes­sion­als whom she termed “the Brain Trust.” They were con­vinced that Fort Det­rick sci­en­tist Bruce Ivins–the “lone nut” who con­ve­nient­ly com­mit­ted sui­cide and was fin­gered as the sole per­pe­tra­tor of the 2001 anthrax attacks–was framed. ” . . . . Among oth­er sub­jects, they dis­cussed  . . . tech­ni­cal details on why they believed that their col­league Bruce Ivins had been framed as the anthrax mail­er . . . .”

Much of the pro­gram cen­ters on the 2001 attacks and the sus­pi­cion that focused on Steven Hat­fill as a pos­si­ble per­pe­tra­tor of them. Although exon­er­at­ed in the attacks, Hat­fill was the focal point of con­sid­er­able sus­pi­cion in con­nec­tion with the event. Our sus­pi­cion is that he is an oper­a­tive of one or anoth­er intel­li­gence agency, CIA being the most prob­a­ble.

We sus­pect that the anthrax attacks were a provo­ca­tion aimed at jus­ti­fy­ing the inva­sion of Iraq and spurring devel­op­ment of the U.S. bio­log­i­cal war­fare capa­bil­i­ty.

Of par­tic­u­lar note is the appar­ent “oper­a­tional Teflon” worn by Hat­fill. Although cir­cum­stan­tial evi­dence point­ed in his direc­tion, he appeared to be alto­geth­er “off lim­its” to inves­tiga­tive ele­ments of Alpha­bet Soup. Don Fos­ter not­ed the unusu­al treat­ment accord­ed to Hat­fill by the pow­ers that be.

Of sig­nif­i­cance, as well, are the numer­ous exam­ples of fore­shad­ow­ing of the foren­sic cir­cum­stances of the anthrax attacks, as well as oth­er “false alarm” inci­dents that occurred before and after the fatal attacks. It requires lit­tle to see state­ments and arti­cles by nota­bles such as Bill Patrick and the seem­ing­ly ubiq­ui­tous Steven Hat­fill as lay­ing a foun­da­tion of cred­i­bil­i­ty for sub­se­quent events.

Note that the Nation­al Insti­tutes of Health have also part­nered with CIA and the Pen­ta­gon, as under­scored by an arti­cle about a BSL‑4 lab at Boston Uni­ver­si­ty.

1.–As the arti­cle notes, as of 2007, the U.S. had “more than a dozen” BSL4 labs–China com­mis­sioned its first as of 2017. a ten­fold increase in fund­ing for BSL4 labs occurred because of the anthrax attacks of 2001. Those attacks might be seen as some­thing of a provo­ca­tion, spurring a dra­mat­ic increase in “dual use” biowar­fare research, under the cov­er of “legit­i­mate” medical/scientific research. In FTR #1128, we hypoth­e­sized about the milieu of Steven Hat­fill and apartheid-linked inter­ests as pos­si­ble authors of a vec­tor­ing of New York City with Sars COV2: ” . . . . Before the anthrax mail­ings of 2001, the Unit­ed States had just two BSL4 labs—both with­in the razor-wire con­fines of gov­ern­ment-owned cam­pus­es. Now, thanks to a ten­fold increase in funding—from $200 mil­lion in 2001 to $2 bil­lion in 2006—more than a dozen such facil­i­ties can be found at uni­ver­si­ties and pri­vate com­pa­nies across the coun­try. . . .”
2.–The Boston Uni­ver­si­ty lab exem­pli­fies the Pen­ta­gon and CIA pres­ence in BSL‑4 facil­i­ty “dual use”: ” . . . . But some sci­en­tists say that argu­ment obscures the true pur­pose of the cur­rent biode­fense boom: to study poten­tial bio­log­i­cal weapons. ‘The uni­ver­si­ty por­trays it as an emerg­ing infec­tious dis­ease lab,’ says David Ozonoff, a Boston Uni­ver­si­ty epi­demi­ol­o­gist whose office is right across the street from the new BSL4 facil­i­ty. ‘But they are talk­ing about study­ing things like small pox and inhala­tion anthrax, which pose no pub­lic health threat oth­er than as bioweapons.’ . . . The orig­i­nal NIH man­date for the lab indi­cat­ed that many groups—including the CIA and Depart­ment of Defense—would be allowed to use the lab for their own research, the nature of which BU might have lit­tle con­trol over. . . .”

As not­ed in past pro­grams, Gilead Sci­ences is very well-con­nect­ed pro­fes­sion­al­ly, with for­mer Sec­re­tary of Defense Don­ald Rums­feld (among oth­er polit­i­cal lumi­nar­ies) serv­ing on its board of direc­tors. Rums­feld was chair­man of the board from 1997 until he left in 2001 to become George W. Bush’s Sec­re­tary of Defense.

Rums­feld was Sec­re­tary of Defense dur­ing the peri­od in which the 2001 anthrax attacks occurred.

Dur­ing the post‑9/11 peri­od of explod­ing gov­ern­ment invest­ments in biode­fense pro­grams, Sec­re­tary of Defense Don­ald Rums­feld was still hold­ing onto mas­sive amounts of Gilead stock, which was increas­ing in val­ue dra­mat­i­cal­ly. What kind of rela­tion­ship did Gilead devel­op with the US biode­fense nation­al secu­ri­ty state dur­ing this peri­od? That seems like a pret­ty impor­tant ques­tion at this point in time.

The U.S. gov­ern­ment was among the cus­tomers whose pur­chas­es drove up the Gilead earn­ings and stock price: ” . . . . What’s more, the fed­er­al gov­ern­ment is emerg­ing as one of the world’s biggest cus­tomers for Tam­i­flu. In July, the Pen­ta­gon ordered $58 mil­lion worth of the treat­ment for U.S. troops around the world, and Con­gress is con­sid­er­ing a mul­ti-bil­lion dol­lar pur­chase. . . .”

Sev­er­al years into his tenure at the Pen­ta­gon, Rums­feld made a killing on the sale of Gilead Sci­ences’ stock, which rose expo­nen­tial­ly in val­ue fol­low­ing its devel­op­ment of Tam­i­flu as a treat­ment for H5N1 avian flu.” . . . . The firm made a loss in 2003, the year before con­cern about bird flu start­ed. Then rev­enues from Tam­i­flu almost quadru­pled, to $44.6m, help­ing put the com­pa­ny well into the black. Sales almost quadru­pled again, to $161.6m last year. Dur­ing this time the share price tre­bled. Mr Rums­feld sold some of his Gilead shares in 2004 reap­ing – accord­ing to the finan­cial dis­clo­sure report he is required to make each year – cap­i­tal gains of more than $5m. The report showed that he still had up to $25m-worth of shares at the end of 2004, and at least one ana­lyst believes his stake has grown well beyond that fig­ure, as the share price has soared. . . .”

Don­ald Rums­feld was a sig­na­to­ry to the 1998 let­ter to Pres­i­dent Clin­ton by the Project for a New Amer­i­can Cen­tu­ry. That let­ter advo­cat­ed a hard­er line against Iraq. ” . . . . Rums­feld has strong ties to the Intel­li­gence Com­mu­ni­ty, as well as to the Atlantic Insti­tute, and is a mem­ber of the Bilder­berg group. He is a finan­cial sup­port­er for the Cen­ter for Secu­ri­ty Pol­i­cy. Rums­feld was one of the sign­ers of the Jan­u­ary 26, 1998, Project for the New Amer­i­can Cen­tu­ry (PNAC) let­ter sent to Pres­i­dent William Jef­fer­son Clin­ton. . . .”

DARPA and the Pen­ta­gon have into the appli­ca­tion of genet­ic engi­neer­ing in order to cre­ate eth­no-spe­cif­ic bio­log­i­cal war­fare weapons, as dis­cussed by the Project for a New Amer­i­can Cen­tu­ry.

In past pro­grams and posts, we have not­ed that DARPA was research­ing  bat-borne coro­n­avirus­es.  One can but won­der to what extent the PNAC doc­trine helped spawn the DARPA research into coro­n­avirus­es and, pos­si­bly, the Covid-19 pan­dem­ic.

FTR #1137 Lyme Disease and Biological Warfare, Part 3

Fur­ther devel­op­ing the links between bio­log­i­cal war­fare research and the Lyme Dis­ease estab­lish­ment, we review infor­ma­tion from FTR #585.

At every turn, Lyme dis­ease research is inex­tri­ca­bly linked with bio­log­i­cal war­fare research. Divid­ed into the “Steere” and “ILADS” camps, the Lyme dis­ease research com­mu­ni­ty is split between the view that the dis­ease is “hard-to-catch, easy-to-cure” and the dia­met­ri­cal­ly opposed view that the dis­ease is very seri­ous and pro­duces long-term neu­ro­log­i­cal dis­or­der. The Steere camp dimin­ish­es the sig­nif­i­cance of the dis­ease and is close­ly iden­ti­fied with bio­log­i­cal war­fare research. At the epi­cen­ter of Lyme dis­ease research (and the Steere camp) are mem­bers of the Epi­dem­ic Intel­li­gence Ser­vice, or EIS. EIS per­son­nel are to be found at every bend in the road of Lyme dis­ease research.

The Bor­re­lia genus has long been researched as a bio­log­i­cal war­fare vec­tor. Note that Unit 731 per­son­nel and their files were put to work for the Unit­ed States after World War II, much like the Project Paper­clip sci­en­tists from Ger­many. ” . . . bor­re­lia were known for their abil­i­ty to adopt dif­fer­ent forms under con­di­tions of stress (such as expo­sure to antibi­otics). Shed­ding their out­er wall, (which is the tar­get of peni­cillin and relat­ed drugs), they could ward off attack and con­tin­ue to exist in the body.  . .”

Much of the pro­gram is devot­ed to excerpt­ing and analy­sis of a 2013 post­ing by Ele­na Cook. This dis­cus­sion of “Spiro­chete War­fare,” in turn, makes lib­er­al use of mate­r­i­al from a 1944 text about Japan’s bio­log­i­cal war­fare pro­gram. This book “Japan’s Secret Weapon,” con­tains a great deal of infor­ma­tion about Japan­ese pio­neer­ing of the use of spiro­chetes as bio­log­i­cal war­fare organ­isms.

This mate­r­i­al is to be con­sid­ered in the his­tor­i­cal and polit­i­cal con­text of the incor­po­ra­tion of the key per­son­nel and files of the noto­ri­ous Japan­ese Unit 731 bio­log­i­cal war­fare divi­sion into the U.S. BW pro­gram after World War II.

Appar­ent­ly decades ahead of their Allied coun­ter­parts, Japan­ese use of spiro­chetes encom­passed a num­ber of impor­tant points to con­sid­er.

1.–The Japan­ese under­stood that “cell-wall defi­cient spiro­chetes, ” “gran­ule” and “L‑forms” had tremen­dous sig­nif­i­cance for bio­log­i­cal war­fare. ” . . . This WW2-era book helps to con­firm what some inves­ti­gat­ing the his­to­ry of Lyme dis­ease have long sus­pect­ed; that the offi­cial denial of the dev­as­tat­ing path­o­gen­ic nature of the gran­ule and oth­er ‘L‑forms’(1) of Lyme-caus­ing Bor­re­lia, is relat­ed to their bio­log­i­cal war­fare sig­nif­i­cance. . .”
2.–” . . . To put it blunt­ly, New­man’s book pro­vides cogent cir­cum­stan­tial evi­dence that many Cell-wall defi­cient forms of Bor­re­lia are in fact weaponized spiro­chetes, nur­tured, cul­tured and opti­mized for aerosol deliv­ery. . .” 
3.–According to author Bar­clay New­man, a com­bined Japan­ese and Nazi bio­log­i­cal war­fare offen­sive against Hawaii using the spiro­chetal dis­ease lep­tospiro­sis against Hawaii two or three years before the attack on Pearl Har­bor: ” . . . . ‘Nazi and Japan­ese sci­en­tists coop­er­at­ed in war­fare against or with spiro­chetes — in Hawaii.’ (orig­i­nal author’s ital­ics). What he is refer­ring to is an excep­tion­al­ly vir­u­lent out­break of the spiro­chetal dis­ease lep­tospiro­sis, also known as Weil’s dis­ease, and known at the time in Ger­many as ‘slime fever’. With offi­cial reports of 44% mor­tal­i­ty from the out­break, New­man states: Con­sult the author­i­ties, and you will find out that, very def­i­nite­ly, so high a mor­tal­i­ty is attained only by Japan­ese strains of spiro­chetes of slime fever. . . .”
4.–According to New­man, the Japan­ese had con­clud­ed that spiro­chetes, although very close to bac­te­ria in form, were not actu­al­ly bac­te­ria and there­fore: ” . . . . a spiro­chete can also break itself into many tiny gran­ules, each as small as the invis­i­ble mol­e­cule of a virus, and each capa­ble of recre­at­ing a new spiro­chete. . . .”
5.–Again, accord­ing to New­man: ” . . . The Japan­ese have report­ed that you can increase the vir­u­lence, or killing pow­er, of these spi­rals by grow­ing them in flesh and blood, of guinea pig or man. . .” This is inter­est­ing to con­sid­er in light of the evi­dence of Lyme Dis­ease as the prod­uct of bio­log­i­cal war­fare. Might some of the “tests” have had the goal of “grow­ing” such organ­isms in humans? ” . . . The resis­tance of many spiro­chetes, includ­ing bor­re­lia, to cul­ture in vit­ro remains a prob­lem for lab sci­en­tists even today. . .”
6.–The “gran­ule” spiro­chete form was found by the Japan­ese to have great val­ue for aerosolized BW appli­ca­tions: ” . . . Ina­da has report­ed that the Japan­ese know how to get virus-like, quite invis­i­ble par­ti­cles or spiro­chete-frag­ments from spe­cial cul­tures of spiro­chetes of infec­tious jaun­dice. The Japan­ese say that such infin­i­tes­i­mals can be used to infect ani­mals and men, by spray­ing droplets con­tain­ing these spiro­chete-cre­at­ing bits into the air, or spread­ing them through water, or scat­ter­ing them in mud or damp soil. . . .”
7.–The above-men­tioned lep­tospiro­sis or “slime fever” may have been used as a “soft­en­ing-up” agent pri­or to Japan­ese inva­sions in World War II” ” . . . ‘Imme­di­ate­ly before the Japan­ese inva­sions of Chi­na, Indo-Chi­na, the Dutch East Indies, and the Malay States, and short­ly before the Japan­ese inva­sion of India and the Japan­ese strokes at Aus­tralia, the very first out­breaks of slime fever were report­ed from every one of these areas’ . . .”
8.–The Japan­ese had dis­cov­ered the appli­ca­tion of infec­tion via mul­ti­ple pathogens. This may have fig­ured into the devel­op­ment of Lyme Dis­ease as well. ” . . . Fuji­mori (sic) was test­ing out the effects of spread­ing two dif­fer­ent par­a­sites into the same guinea pig at the same time. The Japan­ese dis­cov­ered that one par­a­site pro­motes the lethal action of the oth­er. . . .”
9.–The Japan­ese devel­oped with spread­ing spiro­chetal dis­ease via spray­ing droplets into the eyes of tar­gets. We won­der if Willy Burgdor­fer­’s pos­si­ble Lyme infec­tion from dis­eased Rab­bit-urine may have stemmed from this tech­nol­o­gy? This is dis­cussed below. ” . . . ‘Some­times the Japan­ese think up the damnedest exper­i­ments, such as the trans­mis­sion of syphilis by spray­ing the spiro­chetes into the air or into the eyes of ani­mals or vol­un­teers. Infec­tion is thus accom­plished. . . . if you want to spec­u­late fur­ther about the pos­si­bil­i­ties of spiro­chete war­fare, you can be sure that the Japan­ese know how to spread any spiro­chete dis­ease . . . by spray­ing droplets laden with spe­cial­ly cul­tured spiro­chetes. . . .”
10.-Among the dis­eases appar­ent­ly har­nessed for BW use by the Japan­ese was African relaps­ing fever. Willy Burgdor­fer did his grad­u­ate the­sis about this tick-borne spiro­chetal dis­ease and it was researched at length by his men­tor Rudolf Geigy. (Geigy’s pos­si­ble role as an I.G. Far­ben intel­li­gence agent and Paper­clip recruiter is dis­cussed in FTR #1135. Note that some forms of Bor­re­lia Burgdorferi–a pri­ma­ry causative agent of Lyme Disease–resemble the spiro­chete that caus­es relaps­ing fever. ” . . . Relaps­ing fever is caused by the Bor­re­lia genus of bac­te­ria, and is gen­er­al­ly trans­mit­ted to man either by lice, or by the bite of a tick. It is worth not­ing, too, that recent inves­ti­ga­tions into the genet­ic make-up of Lyme bor­re­lia have found some strains appar­ent­ly more close­ly relat­ed to relaps­ing fever Bor­re­lia than to Bor­re­lia burgdor­feri, long con­sid­ered the only bor­re­lia capa­ble of caus­ing Lyme dis­ease. . . .”

Next, the pro­gram details Rudolf Geigy’s work on relaps­ing fever. We sus­pect that his inter­est in such afflic­tions was not as benign and altru­is­tic as his defend­ers main­tain. As men­tioned above, Lyme Dis­ease “dis­cov­er­er” and bio­log­i­cal war­fare vet­er­an Willy Burgdor­fer did his grad­u­ate the­sis on relaps­ing fever.

Again, as men­tioned above, Willy Burgdor­fer con­tract­ed what he felt was Lyme Dis­ease after urine from an infect­ed rab­bit splashed into his eyes. We won­der if some of the tech­niques of using aerosolized spiro­chete gran­ules might have been involved in Willy’s acci­den­tal infec­tion? ” . . . .While he was rins­ing off one of the trays in the sink, Lyme-infect­ed rab­bit urine splashed into his eyes. A few weeks lat­er, on April 13, he noticed five Lyme bul­l’s-eye rash­es under his armpit and on his tor­so. . . .”

In an unpub­lished man­u­script, Willy Burgdor­fer not­ed not only the per­sis­tence of Lyme Dis­ease but its abil­i­ty to remain dor­mant in the ner­vous sys­tem: “. . . . It is now clear that Bor­re­lia burgdor­feri can per­sist with­in the ner­vous sys­tem for years, caus­ing pro­gres­sive ill­ness, and increas­ing evi­dence sug­gests also that the spiro­chete can remain latent there for years before pro­duc­ing clin­i­cal symp­toms. . . .”

Lyme dis­ease is dif­fi­cult to diag­nose, anoth­er fac­tor that makes it ide­al for BW use. Might the Japan­ese Unit 731 research into spiro­chetal war­fare described by Bar­clay New­man have fig­ured into some of the boil­er-plate research that went into the devel­op­ment of Lyme Dis­ease? ” . . . Lyme’s abil­i­ty to evade detec­tion on rou­tine med­ical tests, its myr­i­ad pre­sen­ta­tions which can baf­fle doc­tors by mim­ic­k­ing 100 dif­fer­ent dis­eases, its amaz­ing abil­i­ties to evade the immune sys­tem and antibi­ot­ic treat­ment, would make it an attrac­tive choice to bioweaponeers look­ing for an inca­pac­i­tat­ing agent. Lyme’s abil­i­ties as ‘the great imi­ta­tor’ might mean that an attack could be mis­in­ter­pret­ed as sim­ply a rise in the inci­dence of dif­fer­ent, nat­u­ral­ly-occur­ring dis­eases. . . .”

There is exper­i­men­tal evi­dence that infec­tion with Bor­re­lia burgdor­feri can pro­duce the amy­loid plaques symp­to­matic of Alzheimer’s Dis­ease. ” . . . Here is hypoth­e­sized a tru­ly rev­o­lu­tion­ary notion that round­ed cys­tic forms of Bor­re­lia burgdor­feri are the root cause of the round­ed struc­tures called plaques in the Alzheimer brain. Round­ed “plaques’ in high den­si­ty in brain tis­sue are emblem­at­ic of Alzheimer’s dis­ease (AD). . . .”

The pro­gram con­cludes with more exper­i­men­tal evi­dence of the pro­duc­tion of amy­loid deposits char­ac­ter­is­tic of Alzheimer’s Dis­ease: ” . . . To deter­mine whether an anal­o­gous host reac­tion to that occur­ring in AD could be induced by infec­tious agents, we exposed mam­malian glial and neu­ronal cells in vit­ro to Bor­re­lia burgdor­feri spiro­chetes . . . Mor­pho­log­i­cal changes anal­o­gous to the amy­loid deposits of AD brain were observed fol­low­ing 2–8 weeks of expo­sure to the spiro­chetes. . . These obser­va­tions indi­cate that, by expo­sure to bac­te­ria or to their tox­ic prod­ucts, host respons­es sim­i­lar in nature to those observed in AD may be induced. . . .”

FTR #1136 Lyme Disease and Biological Warfare, Part 2

A recent book about Lyme Dis­ease sets forth cred­i­ble infor­ma­tion that the dis­ease is an out­growth of U.S. bio­log­i­cal war­fare research.

Bit­ten, The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons chron­i­cles the career of Willy Burgdor­fer, a Swiss-born expert on tick and flea-borne dis­eases who spent most of his career research­ing those areas as a U.S. bio­log­i­cal war­fare sci­en­tist.
” . . . . if Willy’s claim was true, a crime against human­i­ty had been com­mit­ted by the U.S. gov­ern­ment, and then cov­ered up. . . ” “Bit­ten,” p. 103.

Lis­ten­ers are emphat­i­cal­ly encour­aged to pur­chase and read this book, as well as shar­ing it with oth­ers.

Author Kris New­by presents sub­stan­tive evi­dence that the dis­ease stems from BW research done by Burgdor­fer and asso­ciates. (Burgdor­fer was the sci­en­tist who “dis­cov­ered” the organ­ism that caus­es Lyme Dis­ease.)

 NB: The mate­r­i­al in this broad­cast is delib­er­ate­ly over­lapped with that in the last pro­gram.

In this post, we high­light infor­ma­tion about what Willy termed “the Swiss Agent”–a rick­ettsia that was present in the vast major­i­ty of Lyme suf­fer­ers test­ed ear­ly in research into the dis­ease.

Even­tu­al­ly, dis­cus­sion of the pos­si­ble role of Swiss Agent dropped out of dis­cus­sion. The dis­ap­pear­ance of the Swiss Agent from the sci­en­tif­ic ana­lyt­i­cal lit­er­a­ture coin­cid­ed with Willy’s tele­phone con­ver­sa­tions with bio­log­i­cal war­fare research vet­er­ans.

Key points of dis­cus­sion:

1.–” . . . . I would engage the sci­en­tif­ic part of his brain in answer­ing my two ques­tions: why the Lyme dis­cov­ery files were miss­ing from the Nation­al Archives, and why images of the organ­ism labeled ‘Swiss Agent’ were locat­ed in the archive fold­ers in the time-frame where one would expect the Lyme spiro­chete pic­tures to be. . . .”
2.–” . . . . He told me that in late 1979, he had test­ed ‘over one hun­dred ticks’ from Shel­ter Island, locat­ed about twen­ty miles from the Lyme out­break, and all but two had an uniden­ti­fied rick­ettsial species inside. It looked like Rick­ettsia mon­tana (now called Rick­ettsia mon­ta­nen­sis) under a micro­scope, a non-dis­ease-caus­ing cousin of the dead­ly Rick­ettsia rick­et­sii, but it was a dif­fer­ent species. . . .”
3.–” . . . .‘You say they’re not look­ing for it any­more?’ I asked. ‘They prob­a­bly paid peo­ple off,’ he said. ‘There are folks up there who have a way to enable that.’ . . .”
4.–” . . . . Next, I showed Willy an unla­beled image of a microbe and asked him what it was. ‘That is a Swiss Agent,’ said Willy. I asked him a series of ques­tions on this microbe and he recit­ed what seemed like well-rehearsed lines: the Swiss Agent is a Rick­ettsia mon­tana-like organ­ism found in the Euro­pean sheep tick, Ixodes Rici­nus, and it doesn’t cause dis­ease in humans. . . .”
5.–” . . . . Then I asked him why he brought sam­ples of it from Switzer­land back to his lab. He replied with the response that he often used when he seemed to know the answer but wasn’t going to divulge it: ‘Ques­tion mark.’. . .”
6.–” . . . . The real ‘smok­ing gun,’ though, was Willy’s hand­writ­ten lab notes on the patient blood tests from the dis­ease out­break in Con­necti­cut. These tests showed the proof-of-pres­ence of what I named ‘Swiss Agent USA,’ the mys­tery rick­ettsia present in most of the patients from the orig­i­nal Lyme out­break, a fact that was nev­er dis­closed in jour­nal arti­cles. It didn’t take a PhD in micro­bi­ol­o­gy to see that almost all the patient blood had react­ed strong­ly to an anti­gen test for a Euro­pean rick­ettsia that Willy had called the Swiss Agent. . . .”
7.–” . . . . In March, he wrote to Ander­son and Steere again: ‘Most spec­i­mens, with a few excep­tions, react­ed only against anti­gens pre­pared from the Swiss Agent.’ In short, the dis­ease clus­ters in Con­necti­cut and Long Island seemed to have been caused by Swiss Agent USA. Then, in April, the Swiss Agent USA rick­ettsia van­ished. It was nev­er again men­tioned in talks, let­ters, inter­views, or jour­nal arti­cles. . . .  There is, with­out a doubt, some­thing sus­pi­cious about the sud­den dis­ap­pear­ance of the Swiss Agent USA from all cor­re­spon­dence. . . .”
8.–The dis­ap­pear­ance of the Swiss Agent USA from the lit­er­a­ture on Lyme Dis­ease cor­re­spond­ed with an impor­tant con­ver­sa­tion that Willy had: ” . . . . It was in the begin­ning of 1980—two years before the first Lyme spiro­chetes were found—that the Swiss Agent USA dis­ap­peared. This about-face coin­cid­ed with a series of dis­cus­sions Willy had with old bioweapons devel­op­ers on the Rick­ettsial Com­mis­sion of the Armed Forces Epi­demi­o­log­i­cal Board, as record­ed in his per­son­al phone log. These sci­en­tists were most cer­tain­ly famil­iar with the secret his­to­ry of inca­pac­i­tat­ing rick­ettsial and viral agent test­ing, and they may have dis­cussed with Willy the pos­si­bil­i­ty of there hav­ing been an undis­closed field test in the Long Island region. . . .”
9.–Roundworms sim­i­lar to organ­isms stud­ied by Willy at the Naval Research Unit in Cairo turned up in some of the ticks: ” . . . . That’s when Willy found par­a­sitic round­worm lar­vae in the main body cav­i­ty of two of the ticks. They were sim­i­lar to the deer worms he’d found in ticks on his 1978 trip to Switzer­land, and sim­i­lar to the round­worms that he, Sonen­shine, and the Naval Research Unit in Cairo had worked with for a project explor­ing the ‘rel­a­tive­ly new field of endo-par­a­sitic trans­mis­sion of dis­ease agents.’ In these exper­i­ments, mul­ti­ple dis­ease agents were put inside mos­qui­to-borne round­worms, accord­ing to an NIH research report from 1961. . . .”
10.–Numerically, it appears that the Swiss Agent rick­ettsias out­num­bered the spiro­chetes that ulti­mate­ly were tabbed as the causative agent for Lyme Dis­ease: ” . . . . When Willy dis­sect­ed 124 more Shel­ter Island deer ticks, 98 per­cent had the new rick­ettsias in them and only 60 per­cent car­ried the new spiro­chetes. Willy thought that either microbe might be caus­ing Lyme dis­ease, but, for unknown rea­sons, this alter­na­tive the­o­ry fell into a black hole. . . .”

Piv­ot­ing to dis­cus­sion of the pol­i­tics of Lyme Dis­ease treat­ment, we note that legal and reg­u­la­to­ry rul­ings have enabled the patent­ing of liv­ing organ­isms and that has exac­er­bat­ed the mon­e­tiz­ing of Lyme Dis­ease treat­ment. That mon­e­ti­za­tion, in turn, has adverse­ly affect­ed the qual­i­ty of care for afflict­ed patients. As we will see lat­er, Willy Burgdor­fer was not the only Lyme Dis­ease researcher to become involved with bio­log­i­cal war­fare research. ” . . . . All of a sud­den, the insti­tu­tions that were sup­posed to be pro­tec­tors of pub­lic health became busi­ness part­ners with Big Phar­ma. The uni­ver­si­ty researchers who had pre­vi­ous­ly shared infor­ma­tion on dan­ger­ous emerg­ing dis­eases were now delay­ing pub­lish­ing their find­ings so they could become entre­pre­neurs and prof­it from patents through their uni­ver­si­ty tech­nol­o­gy trans­fer groups. We essen­tial­ly lost our sys­tem of sci­en­tif­ic checks and bal­ances. And this, in turn, has under­mined patient trust in the insti­tu­tions that are sup­posed to ‘do no harm.’ . . .”

Ms. New­by went up against the “Lyme Dis­ease estab­lish­ment” in an attempt to find out why the dis­ease was being mis-diag­nosed and inef­fec­tive­ly treat­ed. Strik­ing­ly, a FOIA suit she filed was stonewalled for five years, before final­ly yield­ing the doc­u­ments she had so long sought.

The “experts” and their agen­da was neat­ly, and alarm­ing­ly, summed up by Ms. New­by: ” . . . . The emails revealed a dis­turb­ing pic­ture of a nonof­fi­cial group of gov­ern­ment employ­ees and guide­lines authors that had been set­ting the nation­al Lyme dis­ease research agen­da with­out pub­lic over­sight or trans­paren­cy. . . . Bot­tom line, the guide­lines authors reg­u­lar­ly con­vened in gov­ern­ment-fund­ed, closed-door meet­ings with hid­den agen­das that lined the pock­ets of aca­d­e­m­ic researchers with sig­nif­i­cant com­mer­cial inter­ests in Lyme dis­ease tests and vac­cines. A large per­cent­age of gov­ern­ment grants were award­ed to the guide­line authors and/or researchers in their labs. Part of the group’s stat­ed mis­sion, culled from these FOIA emails, was to run a covert ‘dis­in­for­ma­tion war’ and a ‘sociopo­lit­i­cal offen­sive’ to dis­cred­it Lyme patients, physi­cians, and jour­nal­ists who ques­tioned the group’s research and motives. In the FOIA-obtained emails, Lyme patients and their treat­ing physi­cians were called ‘loonies’ and ‘quacks’ by Lyme guide­lines authors and NIH employ­ees. . . .”

Fur­ther devel­op­ing the links between bio­log­i­cal war­fare research and the Lyme Dis­ease estab­lish­ment, we review infor­ma­tion from FTR #585.

At every turn, Lyme dis­ease research is inex­tri­ca­bly linked with bio­log­i­cal war­fare research. Divid­ed into the “Steere” and “ILADS” camps, the Lyme dis­ease research com­mu­ni­ty is split between the view that the dis­ease is “hard-to-catch, easy-to-cure” and the dia­met­ri­cal­ly opposed view that the dis­ease is very seri­ous and pro­duces long-term neu­ro­log­i­cal dis­or­der. The Steere camp dimin­ish­es the sig­nif­i­cance of the dis­ease and is close­ly iden­ti­fied with bio­log­i­cal war­fare research. At the epi­cen­ter of Lyme dis­ease research (and the Steere camp) are mem­bers of the Epi­dem­ic Intel­li­gence Ser­vice, or EIS. EIS per­son­nel are to be found at every bend in the road of Lyme dis­ease research.

The Bor­re­lia genus has long been researched as a bio­log­i­cal war­fare vec­tor.

” . . . . The Bor­re­lia genus of bac­te­ria, which encom­pass­es the Bor­re­lia burgdor­feri species-group (to which Lyme dis­ease is attrib­uted), was stud­ied by the infa­mous WW2 Japan­ese biowar Unit 731, who car­ried out hor­rif­ic exper­i­ments on pris­on­ers in Manchuria, includ­ing dis­sec­tion of live human beings. [iii] Unit 731 also worked on a num­ber of oth­er tick-borne pathogens. . . . . bor­re­lia were known for their abil­i­ty to adopt dif­fer­ent forms under con­di­tions of stress (such as expo­sure to antibi­otics). Shed­ding their out­er wall, (which is the tar­get of peni­cillin and relat­ed drugs), they could ward off attack and con­tin­ue to exist in the body. . . .”

Note that Unit 731 per­son­nel and their files were put to work for the Unit­ed States after World War II, much like the Project Paper­clip sci­en­tists from Ger­many.

Lyme Disease and Biological Warfare, Part 4: Physicians [Financially] Healing Themselves

“Bit­ten, The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons” chron­i­cles the career of Willy Burgdor­fer, a Swiss-born expert on tick and flea-borne dis­eases who spent most of his career research­ing those areas as a U.S. bio­log­i­cal war­fare sci­en­tist. Author Kris
New­by presents sub­stan­tive evi­dence that the dis­ease stems from BW research done by Burgdor­fer and asso­ciates. Lis­ten­ers and read­ers are emphat­i­cal­ly encour­aged to pur­chase and read her book. In this post, we present dis­cus­sion of Ms. New­by’s expose of the insti­tu­tion­al­ly and finan­cial­ly inces­tu­ous rela­tion­ship between bureau­crat­ic and cor­po­rate enti­ties that both reg­u­late, and prof­it from, Lyme Dis­ease. Key “experts” involved with diag­nos­ing and treat­ing the afflic­tion run inter­fer­ence for the sta­tus quo. The “experts” and their agen­da were neat­ly, and alarm­ing­ly, summed up by Ms. New­by: ” . . . . The emails revealed a dis­turb­ing pic­ture of a nonof­fi­cial group of gov­ern­ment employ­ees and guide­lines authors that had been set­ting the nation­al Lyme dis­ease research agen­da with­out pub­lic over­sight or trans­paren­cy. . . . Part of the group’s stat­ed mis­sion, culled from these FOIA emails, was to run a covert ‘dis­in­for­ma­tion war’ and a ‘sociopo­lit­i­cal offen­sive’ to dis­cred­it Lyme patients, physi­cians, and jour­nal­ists who ques­tioned the group’s research and motives. In the FOIA-obtained emails, Lyme patients and their treat­ing physi­cians were called ‘loonies’ and ‘quacks’ by Lyme guide­lines authors and NIH employ­ees. . . .”

FTR #‘s 1135, Lyme Disease and Biological Warfare, Part 1

” . . . . if Willy’s claim was true, a crime against human­i­ty had been com­mit­ted by the U.S. gov­ern­ment, and then cov­ered up. . . ” Bit­ten, p. 103.

A recent book about Lyme Dis­ease sets forth cred­i­ble infor­ma­tion that the dis­ease is an out­growth of U.S. bio­log­i­cal war­fare research.

Bit­ten, The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons chron­i­cles the career of Willy Burgdor­fer, a Swiss-born expert on tick and flea-borne dis­eases who spent most of his career research­ing those areas as a U.S. bio­log­i­cal war­fare sci­en­tist.

Author Kris New­by presents sub­stan­tive evi­dence that the dis­ease stems from BW research done by Burgdor­fer and asso­ciates. (Burgdor­fer was the sci­en­tist who “dis­cov­ered” the organ­ism that caus­es Lyme Dis­ease.)

In past dis­cus­sion of Lyme Dis­ease, we have explored the incor­po­ra­tion of Nazi sci­en­tists via Oper­a­tion Paper­clip into the Amer­i­can bio­log­i­cal war­fare pro­gram and pos­si­ble links between their work and the spread of the dis­ease in Con­necti­cut, across Long Island Sound from Plum Island.

(FTR #‘s 480 and 585 high­light dis­cus­sion about Lyme Dis­ease and bio­log­i­cal war­fare.)

Burgdor­fer­’s entree into the Amer­i­can bio­log­i­cal war­fare pro­gram result­ed from his pro­fes­sion­al rela­tion­ship with long time men­tor and patron Rudolf Geigy. Geigy belonged to a fam­i­ly whose busi­ness, J.R. Geigy AG, was a Swiss chem­i­cal firm mar­ket­ing dyes and insec­ti­cides.

Sig­nif­i­cant­ly, J.R. Geigy, Ciba and San­doz com­prised a Swiss chem­i­cal car­tel formed in the after­math of World War I to com­pete with the I.G. Far­ben car­tel.

(Today, the three com­pa­nies have coa­lesced as the Swiss phar­ma­ceu­ti­cal giant Novar­tis.)

Even­tu­al­ly, the Swiss con­sor­tium was absorbed into, and became a key com­po­nent of, the I.G. Far­ben car­tel. They read­i­ly col­lab­o­rat­ed with the Third Reich:

1.–” . . . . The chap­ters on Switzer­land’s chem­i­cal indus­try are the most embar­rass­ing sec­tion of the com­mis­sion’s report. It is now clear that the direc­tors of Swiss com­pa­nies in Basel were very well aware what was going on at the time in Ger­many and had knowl­edge of the coerced employ­ment of forced labor­ers in their branch plants in Ger­many as well as of the fact that forced labor­ers died as a result of the con­di­tions in which they were held. . . .”
2.–” . . . . sev­er­al lead­ing Swiss chem­i­cal firms — includ­ing JR Geigy, Ciba, San­doz and Hoff­mann-La Roche — put their own inter­ests ahead of human­i­tar­i­an con­cerns in their deal­ing with the Nazis. . . .”
3.–” . . . .The ICE [Inde­pen­dent Com­mis­sion of Experts] con­clud­ed that the chem­i­cal firms’ boss­es in Switzer­land ‘pos­sessed a high lev­el of detailed knowl­edge about the polit­i­cal and eco­nom­ic sit­u­a­tion in Nazi Ger­many... [and] incor­po­rat­ed their knowl­edge... into their eco­nom­ic plan­ning and used it as a basis for deci­sion-mak­ing’ . . . .”
4.–” . . . . ‘Geigy main­tained par­tic­u­lar­ly good rela­tions with Claus Unge­wit­ter, the Reich com­mis­sion­er for chem­i­cals.’ . . .”
5.–” . . . . Dur­ing the war, it [Geigy] pro­duced insec­ti­cides and, most notably, the icon­ic ‘polar red’ dye that col­ored the back­ground of Nazi swasti­ka flags. . . .”

All three Swiss firms [Geigy, San­doz and Ciba] were indict­ed in the Unit­ed States in 1942 because of their col­lab­o­ra­tion with I.G. Far­ben and the Third Reich.

1.–” . . . . Those indict­ed includ­ed duPont; Allied Chem­i­cal and Dye; and Amer­i­can Cyanamid; also Far­ben affil­i­ates the Amer­i­can Ciba, San­doz and Geigy. . . .”
2.–” . . . . A long list of oth­er co-con­spir­a­tors includ­ed the Swiss Ciba, San­doz and Geigy com­pa­nies with Cincin­nati Chem­i­cal works, their joint­ly owned Amer­i­can con­cern . . . .”
3.–” . . . . When Sec­re­tary of War Stim­son and Attor­ney Gen­er­al Bid­dle agreed to post­pone the tri­al until it would not inter­fere with war pro­duc­tion, one Jus­tice Depart­ment offi­cial was quot­ed as say­ing sourly, ‘First they hurt the war effort by their restric­tive prac­tices, and then if caught they use the war effort as an excuse to avoid pros­e­cu­tion.’ . . .”

Use­ful back­ground research with which to flesh out under­stand­ing of the tit­il­lat­ing infor­ma­tion pre­sent­ed by Ms. New­by con­cern­ing Geigy and his activ­i­ties can be obtained by read­ing some of the many books avail­able for down­load on this web­site.

Numer­ous pro­grams present research on the top­ic, includ­ing FTR #511.

A key foun­da­tion­al ele­ment for the dis­cus­sion of Bit­ten is the Pen­tagon’s decades-long research into the genet­ic manip­u­la­tion of micro­bial pathogens.

1.–Nobel Prize win­ner Joshua Leder­berg warned of the con­se­quences for human­i­ty of this work: ” . . . .‘The large-scale deploy­ment of infec­tious agents is a poten­tial threat against the whole species: mutant forms of virus­es could well devel­op that would spread over the earth’s pop­u­la­tion for a new Black Death,’ said Leder­berg in a Wash­ing­ton Post edi­to­r­i­al on Sep­tem­ber 24, 1966. He added, ‘The future of the species is very much bound up with the con­trol of these weapons. Their use must be reg­u­lat­ed by the most thought­ful recon­sid­er­a­tion of U.S. and world pol­i­cy.’ . . .”
2.–The Pen­ta­gon was dis­mis­sive of the warn­ing: ” . . . . A month lat­er, the army’s Bio­log­i­cal Sub­com­mit­tee Muni­tions Advi­so­ry Group thumbed its nose at this ‘nation­al pro­nounce­ment made by promi­nent sci­en­tists.’ . . . The advi­so­ry group then con­tin­ued dis­cussing its plans for genet­ic manip­u­la­tion of microbes, new rick­ettsial and viral agents, and the devel­op­ment of a bal­anced pro­gram for both inca­pac­i­tat­ing and lethal agents. . . .”
3.–By 1962, the mil­i­tary’s plans for devel­op­ment of genet­i­cal­ly mod­i­fied microbes were devel­op­ing in earnest. ” . . . . Fort Detrick’s direc­tor of bio­log­i­cal research, Dr. J.R. Good­low, on Feb­ru­ary 16, 1962 . . . added, ‘Stud­ies of bac­te­r­i­al genet­ics are also in progress with the aim of trans­fer­ring genet­ic deter­mi­nants from one type of organ­ism to another.‘The goal of these exper­i­ments was to make bio­log­i­cal agents more vir­u­lent and resis­tant to antibi­otics. . . .”

The Pen­tagon’s genet­ic manip­u­la­tion of microor­gan­isms for bio­log­i­cal war­fare pur­pos­es involved the Rocky Moun­tain Lab and Willy Burgdor­fer.

1.–” . . . . Bioweapons researchers such as Willy knew that infect­ing large pop­u­la­tions would require expos­ing peo­ple to agents for which they had no nat­ur­al immu­ni­ty. And to do this, researchers would have to import and/or invent new microbes. They were, in essence, play­ing God, cre­at­ing ‘bac­te­ri­o­log­i­cal freaks or mutants,’ by using chem­i­cals, radi­a­tion, ultra­vi­o­let light, and oth­er agents, wrote mod­ern inves­tiga­tive jour­nal­ism pio­neer Jack Ander­son in a Wash­ing­ton Post col­umn on August 27, 1965. . . .”
2.–” . . . . Willy had already been con­duct­ing a tri­al-and-error style of genet­ic manip­u­la­tion in the same way that a corn farmer or a hog grow­er selec­tive­ly breeds strains that result in desired out­comes. He was grow­ing microbes inside ticks, hav­ing the ticks feed on ani­mals, and then har­vest­ing the microbes from the ani­mals that exhib­it­ed the lev­el of ill­ness the mil­i­tary had request­ed. . . .”
3.–” . . . . He was also simul­ta­ne­ous­ly mix­ing bac­te­ria and virus­es inside ticks, lever­ag­ing the virus’s innate abil­i­ty to manip­u­late bac­te­r­i­al genes in order to repro­duce, and thus accel­er­at­ing the rate of muta­tions and desir­able new bac­te­r­i­al traits. In 1966, Fort Detrick’s Bio­log­i­cal Sub­com­mit­tee Muni­tions Advi­so­ry Group put this emerg­ing research area at the top of its pri­or­i­ties, describ­ing it as ‘Research in micro­bial genet­ics con­cerned with aspects of trans­for­ma­tion, trans­duc­tion, and recom­bi­na­tion.’ . .”

 Inter­viewed by an indie film­mak­er named Tim Grey, Willy Burgdor­fer dis­cussed the devel­op­ment of Lyme Dis­ease as a bio­log­i­cal war­fare weapon. It was Burgdor­fer who “dis­cov­ered” the spiro­chete that caused Lyme Dis­ease in 1982. As we will see lat­er, it appears that more than one organ­ism is involved with Lyme Dis­ease.

1.–” . . . . Willy paused, then replied, ‘Ques­tion: Has [sic] Bor­re­lia Burgdor­feri have the poten­tial for bio­log­i­cal war­fare?’ As tears welled up in Willy’s eyes, he con­tin­ued, ‘Look­ing at the data, it already has. If the organ­ism stays with­in the sys­tem, you won’t even rec­og­nize what it is. In your lifes­pan, it can explode . . . We eval­u­at­ed. You nev­er deal with that [as a sci­en­tist]. You can sleep bet­ter.’ . . .”
2.–” . . . . Lat­er in the video, Grey cir­cled back to this top­ic and asked, ‘If there’s an emer­gence of a brand-new epi­dem­ic that has the tenets of all of those things that you put togeth­er, do you feel respon­si­ble for that?’ ‘Yeah. . . .’ ”
3.–” . . . . Grey asked him the one ques­tion, the only ques­tion, he real­ly cared about: ‘Was the pathogen that you found in the tick that Allen Steere [the Lyme out­break inves­ti­ga­tor] gave you the same pathogen or sim­i­lar, or a gen­er­a­tional muta­tion, of the one you pub­lished in the paper . . . the paper from 1952?’ ”
4.–” . . . . The left side of his mouth briefly curled up, as if he is think­ing, ‘Oh, well.’ Then anger flash­es across his face. ‘Yah,’ he said, more in Ger­man than Eng­lish. . . .”
5.–” . . . . It was a stun­ning admis­sion from one of the world’s fore­most author­i­ties on Lyme dis­ease. If it was true, it meant that Willy had left out essen­tial data from his sci­en­tif­ic arti­cles on the Lyme dis­ease out­break, and that as the dis­ease spread like a wild­fire in the North­east and Great Lakes regions of the Unit­ed States, he was part of the cov­er-up of the truth. . . It had been cre­at­ed in a mil­i­tary bioweapons lab for the spe­cif­ic pur­pose of harm­ing human beings. . . . ”

To con­clude the pro­gram, we high­light infor­ma­tion about what Willy termed “the Swiss Agent”–a rick­ettsia that was present in the vast major­i­ty of Lyme suf­fer­ers test­ed ear­ly in research into the dis­ease. Note that this ele­ment of analy­sis will be con­tin­ued in our next pro­gram.

Even­tu­al­ly, dis­cus­sion of the pos­si­ble role of Swiss Agent dropped out of dis­cus­sion. The dis­ap­pear­ance of the Swiss Agent from the sci­en­tif­ic ana­lyt­i­cal lit­er­a­ture coin­cid­ed with Willy’s tele­phone con­ver­sa­tions with bio­log­i­cal war­fare research vet­er­ans.

Key points of dis­cus­sion:

1.–” . . . . I would engage the sci­en­tif­ic part of his brain in answer­ing my two ques­tions: why the Lyme dis­cov­ery files were miss­ing from the Nation­al Archives, and why images of the organ­ism labeled ‘Swiss Agent’ were locat­ed in the archive fold­ers in the time-frame where one would expect the Lyme spiro­chete pic­tures to be. . . .”
2.–” . . . . He told me that in late 1979, he had test­ed ‘over one hun­dred ticks’ from Shel­ter Island, locat­ed about twen­ty miles from the Lyme out­break, and all but two had an uniden­ti­fied rick­ettsial species inside. It looked like Rick­ettsia mon­tana (now called Rick­ettsia mon­ta­nen­sis) under a micro­scope, a non-dis­ease-caus­ing cousin of the dead­ly Rick­ettsia rick­et­sii, but it was a dif­fer­ent species. . . .”
3.–” . . . .‘You say they’re not look­ing for it any­more?’ I asked. ‘They prob­a­bly paid peo­ple off,’ he said. ‘There are folks up there who have a way to enable that.’ . . .”
4.–” . . . . Next, I showed Willy an unla­beled image of a microbe and asked him what it was. ‘That is a Swiss Agent,’ said Willy. I asked him a series of ques­tions on this microbe and he recit­ed what seemed like well-rehearsed lines: the Swiss Agent is a Rick­ettsia mon­tana-like organ­ism found in the Euro­pean sheep tick, Ixodes Rici­nus, and it doesn’t cause dis­ease in humans. . . .”
5.–” . . . . Then I asked him why he brought sam­ples of it from Switzer­land back to his lab. He replied with the response that he often used when he seemed to know the answer but wasn’t going to divulge it: ‘Ques­tion mark.’. . .”
6.–” . . . . The real ‘smok­ing gun,’ though, was Willy’s hand­writ­ten lab notes on the patient blood tests from the dis­ease out­break in Con­necti­cut. These tests showed the proof-of-pres­ence of what I named ‘Swiss Agent USA,’ the mys­tery rick­ettsia present in most of the patients from the orig­i­nal Lyme out­break, a fact that was nev­er dis­closed in jour­nal arti­cles. It didn’t take a PhD in micro­bi­ol­o­gy to see that almost all the patient blood had react­ed strong­ly to an anti­gen test for a Euro­pean rick­ettsia that Willy had called the Swiss Agent. . . .”

Lyme Disease and Biological Warfare, Part 3: The “Swiss Agent”

“Bit­ten, The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons” chron­i­cles the career of Willy Burgdor­fer, a Swiss-born expert on tick and flea-borne dis­eases who spent most of his career research­ing those areas as a U.S. bio­log­i­cal war­fare sci­en­tist. Author Kris
New­by presents sub­stan­tive evi­dence that the dis­ease stems from BW research done by Burgdor­fer and asso­ciates. Lis­ten­ers and read­ers are emphat­i­cal­ly encour­aged to pur­chase and read her book. In this post, we high­light infor­ma­tion about what Willy termed “the Swiss Agent”–a rick­ettsia that was present in the vast major­i­ty of Lyme suf­fer­ers test­ed ear­ly in research into the dis­ease. The dis­ap­pear­ance of the Swiss Agent USA from the lit­er­a­ture on Lyme Dis­ease cor­re­spond­ed with an impor­tant con­ver­sa­tion that Willy had: ” . . . . It was in the begin­ning of 1980—two years before the first Lyme spiro­chetes were found—that the Swiss Agent USA dis­ap­peared. This about-face coin­cid­ed with a series of dis­cus­sions Willy had with old bioweapons devel­op­ers on the Rick­ettsial Com­mis­sion of the Armed Forces Epi­demi­o­log­i­cal Board, as record­ed in his per­son­al phone log. These sci­en­tists were most cer­tain­ly famil­iar with the secret his­to­ry of inca­pac­i­tat­ing rick­ettsial and viral agent test­ing, and they may have dis­cussed with Willy the pos­si­bil­i­ty of there hav­ing been an undis­closed field test in the Long Island region. . . .”

Lyme Disease and Biological Warfare, Part 2

“Bit­ten, The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons” chron­i­cles the career of Willy Burgdor­fer, a Swiss-born expert on tick and flea-borne dis­eases who spent most of his career research­ing those areas as a U.S. bio­log­i­cal war­fare sci­en­tist. Author Kris
New­by presents sub­stan­tive evi­dence that the dis­ease stems from BW research done by Burgdor­fer and asso­ciates. Lis­ten­ers and read­ers are emphat­i­cal­ly encour­aged to pur­chase and read her book. A key foun­da­tion­al ele­ment for the dis­cus­sion of “Bit­ten” is the Pen­tagon’s decades-long research into the genet­ic manip­u­la­tion of micro­bial pathogens. Nobel Prize win­ner Joshua Leder­berg warned of the con­se­quences for human­i­ty of this work: ” . . . .‘The large-scale deploy­ment of infec­tious agents is a poten­tial threat against the whole species: mutant forms of virus­es could well devel­op that would spread over the earth’s pop­u­la­tion for a new Black Death,’ said Leder­berg in a Wash­ing­ton Post edi­to­r­i­al on Sep­tem­ber 24, 1966. . . .” Dr. Leder­berg’s warn­ing went unheed­ed: ” . . . . Fort Detrick’s direc­tor of bio­log­i­cal research, Dr. J.R. Good­low, on Feb­ru­ary 16, 1962 . . . added, ‘Stud­ies of bac­te­r­i­al genet­ics are also in progress with the aim of trans­fer­ring genet­ic deter­mi­nants from one type of organ­ism to another.‘The goal of these exper­i­ments was to make bio­log­i­cal agents more vir­u­lent and resis­tant to antibi­otics. . . .” Lyme Dis­ease “dis­cov­er­er” Willy Burgdor­fer focused on genet­ic manip­u­la­tion: ” . . . . He was also simul­ta­ne­ous­ly mix­ing bac­te­ria and virus­es inside ticks, lever­ag­ing the virus’s innate abil­i­ty to manip­u­late bac­te­r­i­al genes in order to repro­duce, and thus accel­er­at­ing the rate of muta­tions and desir­able new bac­te­r­i­al traits. In 1966, Fort Detrick’s Bio­log­i­cal Sub­com­mit­tee Muni­tions Advi­so­ry Group put this emerg­ing research area at the top of its pri­or­i­ties, describ­ing it as ‘Research in micro­bial genet­ics con­cerned with aspects of trans­for­ma­tion, trans­duc­tion, and recom­bi­na­tion.’ . .”

Lyme Disease and Biological Warfare

“Bit­ten, The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons” chron­i­cles the career of Willy Burgdor­fer, a Swiss-born expert on tick and flea-borne dis­eases who spent most of his career research­ing those areas as a U.S. bio­log­i­cal war­fare sci­en­tist. Author Kris
New­by presents sub­stan­tive evi­dence that the dis­ease stems from BW research done by Burgdor­fer and asso­ciates. Lis­ten­ers and read­ers are emphat­i­cal­ly encour­aged to pur­chase and read her book. Inter­viewed by an indie film­mak­er named Tim Grey, Willy Burgdor­fer dis­cussed the devel­op­ment of Lyme Dis­ease as a bio­log­i­cal war­fare weapon. It was Burgdor­fer who “dis­cov­ered” the spiro­chete that caused Lyme Dis­ease in 1982. As we will see lat­er, it appears that more than one organ­ism is involved with Lyme Dis­ease. ” . . . . Final­ly, after three hours and four­teen min­utes, Grey asked him the one ques­tion, the only ques­tion, he real­ly cared about: ‘was the pathogen that you found in the tick that Allen Steere [the Lyme out­break inves­ti­ga­tor] gave you the same pathogen or sim­i­lar, or a gen­er­a­tional muta­tion, of the one you pub­lished in the paper . . . the paper from 1952?’ In response, Willy crossed his arms defen­sive­ly, took a deep breath, and stared into the cam­era for forty-three seconds—an eter­ni­ty. Then he looked away, down and to the right; he appeared to be work­ing through an inter­nal debate. The left side of his mouth briefly curled up, as if he is think­ing, ‘Oh, well.’ Then anger flash­es across his face. ‘Yah,’ he said, more in Ger­man than Eng­lish. . . . It was a stun­ning admis­sion from one of the world’s fore­most author­i­ties on Lyme dis­ease. . . . He seemed to be say­ing that Lyme wasn’t a nat­u­ral­ly occur­ring germ. . . .”

FTR #1134 Bio-Psy-Op Apocalypse Now, Part 9: Covid-19 Updates

As indi­cat­ed by the title of the pro­gram, this broad­cast updates var­i­ous arti­cles and book excerpts con­cern­ing Covid-19.

A Dai­ly Mail Online [UK] arti­cle sets forth two bogus papers con­tend­ing that the SARS CoV‑2 virus was genet­i­cal­ly engi­neered by the Chi­nese as a bioweapon in a lab­o­ra­to­ry and that it “escaped.” Note the cham­pi­oning of one of the papers by a for­mer head of MI6 and the author­ship of the sec­ond by The Epoch Times, the paper of the Falun Gong cult. Linked to CIA, Steve Ban­non’s anti-Chi­na milieu and the Trump admin­is­tra­tion, the orga­ni­za­tion is a fas­cist mind con­trol cult dis­cussed in numer­ous shows, includ­ing FTR #‘s 1089 and 1090. 

1.–“A for­mer MI6 chief was yes­ter­day accused by Gov­ern­ment offi­cials of ped­dling ‘fan­ci­ful claims’ that coro­n­avirus was acci­den­tal­ly cre­at­ed in a Chi­nese lab­o­ra­to­ry. British secu­ri­ty agen­cies believe Covid-19 is not a man-made virus and is ‘high­ly like­ly’ to have occurred nat­u­ral­ly and spread to humans through ani­mals. And Health Sec­re­tary Matt Han­cock has said there is ‘no evi­dence’ to back up the the­o­ry that it orig­i­nat­ed in a lab­o­ra­to­ry. But Sir Richard Dearlove, who was head of the MI6 from 1999 to 2004, cit­ed a recent report claim­ing the dis­ease was acci­den­tal­ly man­u­fac­tured by Chi­nese sci­en­tists.
2.–“ ‘I do think that this start­ed as an acci­dent,’ Sir Richard told The Dai­ly Telegraph’s ‘Plan­et Nor­mal’ pod­cast. ‘It rais­es the issue: if Chi­na ever were to admit respon­si­bil­i­ty, does it pay repa­ra­tions? I think it will make every coun­try in the world rethink how it treats its rela­tion­ship with Chi­na.’ He added: ‘Look at the sto­ries... of attempts by the [Bei­jing] lead­er­ship to lock down any debate about the ori­gins of the pan­dem­ic and the way peo­ple have been arrest­ed or silenced.’ . . . . The paper – co-authored by Pro­fes­sor Angus Dal­gleish, a renowned oncol­o­gist and vac­cine researcher who works at St George’s Hos­pi­tal, Uni­ver­si­ty of Lon­don, and Birg­er Sorensen, a Nor­we­gian virol­o­gist – con­tains none of the stark alle­ga­tions that orig­i­nal­ly stunned its review­ers.
3..–“The ini­tial paper that trig­gered wild rumours failed strin­gent tests of ver­i­fi­ca­tion and is under­stood to have been reject­ed in April by emi­nent inter­na­tion­al jour­nals such as Nature and the Jour­nal of Virol­o­gy. Bio­med­ical experts from the Fran­cis Crick Insti­tute and Impe­r­i­al Col­lege Lon­don are said to have refut­ed its con­clu­sions. Then one of the paper’s co-authors, Dr John Fredrik Moxnes, chief sci­en­tif­ic advis­er to the Nor­we­gian mil­i­tary, asked for his name to be with­drawn. This week, after numer­ous rewrites, the paper was pub­lished by the Quar­ter­ly Review of Bio­physics Dis­cov­ery. And those orig­i­nal world-shak­ing con­clu­sions have now with­ered to innu­en­do. No accu­sa­tion of Chi­nese manip­u­la­tion appears. . . .”
4.–”. . . . Back in April, a slick­ly pro­duced inves­tiga­tive doc­u­men­tary, Track­ing Down The Ori­gin Of The Wuhan Coro­n­avirus, was released online. It claimed con­clu­sive proof that the Covid-19 virus had been cre­at­ed as a bio­log­i­cal ‘weapon of mass destruc­tion’ in a Chi­nese lab. . . .”
5.–“At first sight, it seemed a shock­ing­ly con­vinc­ing piece of jour­nal­ism. On behalf of this news­pa­per, I cross-checked every claim: The experts it cit­ed and the fac­tu­al evi­dence unearthed. I also researched the back­grounds of its mak­ers. I then approached some of the world’s best inde­pen­dent sci­en­tif­ic author­i­ties to ask their opin­ion. They all agreed – this entic­ing­ly spicy sto­ry just did­n’t stand up.”
6.–“It had been pro­duced by a US based anti-Chi­nese gov­ern­ment media organ­i­sa­tion called the Epoch Times. Its ‘experts’ were vet­er­an hard-Right­ists. Most damn­ing­ly, its sci­en­tif­ic ‘facts’ were twist­ed out of shape.So much, then, for the Chi­nese-man­u­fac­tured coro­n­avirus con­spir­a­cy . . .”

Steve Ban­non is at the epi­cen­ter of the anti-Chi­na effort and–to no one’s surprise–never real­ly left the Trump White House.

When assess­ing Ban­non as a polit­i­cal ani­mal, one should nev­er for­get that among the impor­tant ide­o­log­i­cal influ­ences on him is Julius Evola, an Ital­ian fas­cist who found Mus­soli­ni too mod­er­ate and ulti­mate­ly took his cues from the Nazi SS, who were financ­ing his work by the end of World War II.

” . . . . Don­ald Trump’s light­ning-rod 2016 cam­paign boss and for­mer White House chief strate­gist who was ban­ished from the West Wing in 2017 has qui­et­ly crept back into 1600 Penn­syl­va­nia Ave., reestab­lish­ing ties to staffers, par­tic­u­lar­ly with regard to his pet issues of Chi­na and immi­gra­tion. . . . Anoth­er for­mer admin­is­tra­tion offi­cial told The Post that Ban­non nev­er real­ly left the White House after he was fired, main­tain­ing con­tacts and keep­ing up reg­u­lar chan­nels of com­mu­ni­ca­tions with offi­cials there. . . .”

In addi­tion, as dis­cussed in FTR #‘s 1111 and 1112, Ban­non is part of a net­work that includes J. Kyle Bass and Tom­my Hicks, Jr. This nexus involves asym­met­ri­cal invest­ing with regard to the Hong Kong and Chi­nese economies and the inter-agency gov­ern­men­tal net­works involved in both overt and covert anti-Chi­na poli­cies imple­ment­ed by Team Trump. As will be seen below, they also are net­work­ing with the mis-named “Sci­en­tists to Stop Covid-19.” In that regard, they are also help­ing steer pol­i­cy that con­trols devel­op­ment of treat­ment and vac­cines for Covid-19. The man­age­ment of drug and vac­cine devel­op­ment, in turn, dou­bles back to mar­ket-dri­ving invest­ment dynam­ics.

An inter­est­ing sum­ma­tion of char­ac­ter­is­tics of a “delib­er­ate” epi­dem­ic are eval­u­at­ed against the find­ing that New York City was the epi­cen­ter of the U.S. Covid-19 out­break: 

Bit­ten: The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons by Kris New­by; Harper­Collins [HC]; Copy­right 2019 by Kris New­by; ISBN 9780062896728; p. 185.

Poten­tial epi­demi­o­log­i­cal clues to a delib­er­ate epi­dem­ic:

Clue no. 1–A high­ly unusu­al event with large num­bers of casu­al­ties: Check!

Clue no. 2–Higher mor­bid­i­ty or mor­tal­i­ty than is expect­ed. Check!

Clue no. 3–Uncommon dis­ease. Check!

Clue no. 4–Point-source out­break. Check!

Clue no. 5–Multiple epi­demics. Check! (Glob­al pan­dem­ic)

                      –Z. F. Dem­bek, et al., “Dis­cern­ment Between Delib­er­ate and Nat­ur­al Infec­tious Dis­ease Out­breaks”

The pre­vail­ing view of the Covid-19 out­break con­tends that the Amer­i­can out­break spread out­ward from New York City. The strain of SARS CoV‑2 that appeared in New York came, in turn, from Europe. 

This does­n’t make sense. There were con­firmed cas­es of the virus on the West Coast that did not come from New York. A Euro­pean strain of the virus trans­mit­ted to New York City would have come in via air. In such an event, there would have been a well-doc­u­ment­ed out­break of Covid-19 among flight atten­dants, who oper­ate in close con­tact with pas­sen­gers in cramped cir­cum­stances, as well as expe­ri­enc­ing jet lag, which com­pro­mis­es the immune sys­tem.

Next, we review an aspect of the 2001 anthrax attacks. We high­light­ed the 2001 anthrax attacks in con­nec­tion with the Covid-19 out­break in New York City in FTR #1128.

We note that the Anthrax attacks appear to have oper­at­ed in over­lap­ping con­texts, includ­ing jus­ti­fi­ca­tion for the war in Iraq. 

The 2001 anthrax attacks appear to have served as a provo­ca­tion that jus­ti­fied a ten-fold increase in spend­ing for bio­log­i­cal war­fare devel­op­ment. The num­ber of BSL‑4 labs (hav­ing dual civil­ian and mil­i­tary use) increased from two in 2001, to a dozen in 2007.

This increase occurred while Don­ald Rums­feld was George W. Bush’s sec­re­tary of defense. He went to that posi­tion from being Chair­man of the Board of Direc­tors for Gilead Sci­ences, the man­u­fac­tur­er of remde­sivir.

We will delve into the pol­i­tics of the anthrax attacks in the future.

In the con­text of the above arti­cle, note that the Nation­al Insti­tutes of Health have also part­nered with CIA and the Pen­ta­gon, as under­scored by an arti­cle about a BSL‑4 lab at Boston Uni­ver­si­ty. Note that Europe and the U.S. have twelve BSL4 labs apiece. Tai­wan has two. Chi­na has one:

1.–As the arti­cle notes, as of 2007, the U.S. had “more than a dozen” BSL4 labs–China com­mis­sioned its first as of 2017. a ten­fold increase in fund­ing for BSL4 labs occurred because of the anthrax attacks of 2001. Those attacks might be seen as some­thing of a provo­ca­tion, spurring a dra­mat­ic increase in “dual use” biowar­fare research, under the cov­er of “legit­i­mate” medical/scientific research. In FTR #1128, we hypoth­e­sized about the milieu of Stephen Hat­fill and apartheid-linked inter­ests as pos­si­ble authors of a vec­tor­ing of New York City with Sars COV2: ” . . . . Before the anthrax mail­ings of 2001, the Unit­ed States had just two BSL4 labs—both with­in the razor-wire con­fines of gov­ern­ment-owned cam­pus­es. Now, thanks to a ten­fold increase in funding—from $200 mil­lion in 2001 to $2 bil­lion in 2006—more than a dozen such facil­i­ties can be found at uni­ver­si­ties and pri­vate com­pa­nies across the coun­try. . . .”
2.–The Boston Uni­ver­si­ty lab exem­pli­fies the Pen­ta­gon and CIA pres­ence in BSL‑4 facil­i­ty “dual use”: ” . . . . But some sci­en­tists say that argu­ment obscures the true pur­pose of the cur­rent biode­fense boom: to study poten­tial bio­log­i­cal weapons. ‘The uni­ver­si­ty por­trays it as an emerg­ing infec­tious dis­ease lab,’ says David Ozonoff, a Boston Uni­ver­si­ty epi­demi­ol­o­gist whose office is right across the street from the new BSL4 facil­i­ty. ‘But they are talk­ing about study­ing things like small pox and inhala­tion anthrax, which pose no pub­lic health threat oth­er than as bioweapons.’ . . . The orig­i­nal NIH man­date for the lab indi­cat­ed that many groups—including the CIA and Depart­ment of Defense—would be allowed to use the lab for their own research, the nature of which BU might have lit­tle con­trol over. . . .”

Piv­ot­ing to dis­cus­sion and review of the polit­i­cal, finan­cial and cor­po­rate con­nec­tions to the devel­op­ment of med­i­c­i­nal treat­ments for, and vac­cines to pre­vent, Covid-19, we recap details rel­e­vant to the extra­or­di­nary tim­ing of a 4/29 announce­ment of favor­able results for a tri­al of remde­sivir. That announce­ment drove equi­ties mar­kets high­er and was ben­e­fi­cial to the stock of Gilead Sci­ences.

We present a Stat News arti­cle on the inter­nal delib­er­a­tions behind the deci­sions to mod­i­fy the NIAID study. Of par­tic­u­lar sig­nif­i­cance is the DSMB delib­er­a­tion. Note the time­line of the DSMB delib­er­a­tion, com­bined with the announce­ment on 4/29 that drove the mar­kets high­er.

1.–The deci­sion was made to cut it short before the ques­tion of remdesivir’s impact on mor­tal­i­ty could be answered: ” . . . .The Nation­al Insti­tute of Aller­gy and Infec­tious Dis­eases has described to STAT in new detail how it made its fate­ful deci­sion: to start giv­ing remde­sivir to patients who had been assigned to receive a place­bo in the study, essen­tial­ly lim­it­ing researchers’ abil­i­ty to col­lect more data about whether the drug saves lives — some­thing the study, called ACTT‑1, sug­gests but does not prove. In the tri­al, 8% of the par­tic­i­pants giv­en remde­sivir died, com­pared with 11.6% of the place­bo group, a dif­fer­ence that was not sta­tis­ti­cal­ly sig­nif­i­cant. A top NIAID offi­cial said he had no regrets about the deci­sion. ‘There cer­tain­ly was una­nim­i­ty with­in the insti­tute that this was the right thing to do,’ said H. Clif­ford Lane, NIAID’s clin­i­cal direc­tor. . . .”
2.–In addi­tion, patients sched­uled to receive place­bo received remde­sivir, instead. ” . . . . Steven Nis­sen, a vet­er­an tri­al­ist and car­di­ol­o­gist at the Cleve­land Clin­ic, dis­agreed that giv­ing place­bo patients remde­sivir was the right call. ‘I believe it is in society’s best inter­est to deter­mine whether remde­sivir can reduce mor­tal­i­ty, and with the release of this infor­ma­tion doing a place­bo-con­trolled tri­al to deter­mine if there is a mor­tal­i­ty ben­e­fit will be very dif­fi­cult,’ he said. ‘The ques­tion is: Was there a route, or is there a route, to deter­mine if the drug can pre­vent death?’ The deci­sion is ‘a lost oppor­tu­ni­ty,’ he said. . . .”
3.–Steven Nis­sen was not alone in his crit­i­cism of the NIAID’s deci­sion. ” . . . .Peter Bach, the direc­tor of the Cen­ter for Health Pol­i­cy and Out­comes at Memo­r­i­al Sloan Ket­ter­ing Can­cer Cen­ter, agreed with Nis­sen. ‘The core under­stand­ing of clin­i­cal research par­tic­i­pa­tion and clin­i­cal research con­duct is we run the tri­al rig­or­ous­ly to pro­vide the most accu­rate infor­ma­tion about the right treat­ment,’ he said. And that answer, he argued, should ide­al­ly have deter­mined whether remde­sivir saves lives. The rea­son we have shut our whole soci­ety down, Bach said, is not to pre­vent Covid-19 patients from spend­ing a few more days in the hos­pi­tal. It is to pre­vent patients from dying. ‘Mor­tal­i­ty is the right end­point,’ he said. . . .”
4.–Not only was the admin­is­tra­tion of remde­sivir instead of place­bo pri­or­i­tized, but the NIAID study itself was atten­u­at­ed! ” . . . . But the change in the study’s main goal also changed the way the study would be ana­lyzed. Now, the NIAID decid­ed, the analy­sis would be cal­cu­lat­ed when 400 patients out of the 1,063 patients the study enrolled had recov­ered. If remde­sivir turned out to be much more effec­tive than expect­ed, ‘inter­im’ analy­ses would be con­duct­ed at a third and two-thirds that number.The job of review­ing these analy­ses would fall to a com­mit­tee of out­side experts on what is known as an inde­pen­dent data and safe­ty mon­i­tor­ing board, or DSMB. . . .”
5.–The per­for­mance of the DSMB for the remde­sivir study is note­wor­thy: ” . . . . But the DSMB for the remde­sivir study did not ever meet for an inter­im effi­ca­cy analy­sis, Lane said. All patients had been enrolled by April 20. The data for a DSMB meet­ing was cut off on April 22. The DSMB met and, on April 27, it made a rec­om­men­da­tion to the NIAID. . . .”
The DSMB meet­ing on 4/27 deter­mined the switch from place­bo to remde­sivir. Of para­mount impor­tance is the fact that this was JUST BEFORE the 4/29 announce­ment that drove the mar­kets high­er and the same day on which key Trump aide–and for­mer Gilead Sci­ences lob­by­ist Joe Gro­gan resigned! ” . . . . . That deci­sion, Lane said, led the NIAID to con­clude that patients who had been giv­en place­bo should be offered remde­sivir, some­thing that start­ed hap­pen­ing after April 28. . . .”
6.–Dr. Ethan Weiss gave an accu­rate eval­u­a­tion of the NIAID study: ” . . . . ‘We’ve squan­dered an incred­i­ble oppor­tu­ni­ty to do good sci­ence,’ [Dr. Ethan] Weiss said. ‘If we could ever go back and do some­thing all over, it would be the infra­struc­ture to actu­al­ly learn some­thing. Because we’re not learn­ing enough.’ . . . .”

The remark­able han­dling of the NIAID study, the tim­ing of the announce­ment of the alto­geth­er lim­it­ed suc­cess of the atten­u­at­ed tri­al and the rise in equi­ties as a result of the announce­ment may be best under­stood in the con­text of the role played in Trump pan­dem­ic deci­sion-mak­ing by an elite group of bil­lion­aires and scientists–including con­vict­ed felon Michael Milken (the “junk bond king”).

1.–” . . . . Call­ing them­selves ‘Sci­en­tists to Stop COVID-19,’ the col­lec­tion of top researchers, bil­lion­aires and indus­try cap­tains will act as an ‘ad hoc review board’ for the tor­rent of coro­n­avirus research, ‘weed­ing out’ flawed data before it reach­es pol­i­cy­mak­ers, the Wall Street Jour­nal report­ed on Mon­day. They are also act­ing as a go-between for phar­ma­ceu­ti­cal com­pa­nies seek­ing to build a com­mu­ni­ca­tion chan­nel with Trump admin­is­tra­tion offi­cials. The group . . . . has advised Nick Ayers, an aide to Vice Pres­i­dent Mike Pence, as well as oth­er agency heads, in the past month. Pence is head­ing up the White House coro­n­avirus task force. . . .”
2.–” . . . The brainy bunch is led by Thomas Cahill, a 33-year-old doc­tor who became a ven­ture cap­i­tal­ist . . . . Cahill’s clout comes from build­ing con­nec­tions through his invest­ment firm, New­path Part­ners, with Sil­i­con Valley’s Peter Thiel, the founder of Pay­Pal, and bil­lion­aire busi­ness­men Jim Palot­ta and Michael Milken. . . .”

Note that Peter Thiel played a dom­i­nant role in bankrolling New­path Part­ners, and the oth­er finan­cial angel who ele­vat­ed Cahill–Brian Sheth–introduced him to Tom­my Hicks, Jr., the co-chair­man of the RNC. In FTR #‘s 1111 and 1112, we looked at Hicks’ net­work­ing with Steve Ban­non asso­ciate J. Kyle Bass, as well as his role in the inter-agency net­works dri­ving the anti-Chi­na effort.

” . . . . At the helm of the effort: The 33-year-old and very-much-under-the-radar ven­ture cap­i­tal­ist Tom Cahill, who leads life sci­ences-focused New­path Part­ners. Cahill com­plet­ed his M.D. and PhD at Duke Uni­ver­si­ty a mere two years ago before land­ing at blue-chip invest­ment firm Rap­tor Group through a friend. He went on to found New­path with some $125 mil­lion after impress­ing well-con­nect­ed names like ven­ture cap­i­tal­ist Peter Thiel and Vista Equi­ty Part­ners co-founder Bri­an Sheth. . . . It was through Sheth, for exam­ple, that Sci­en­tists to Stop Covid-19 con­nect­ed with the co-chair­man of the Repub­li­can Nation­al Com­mit­tee, Thomas Hicks Jr. . . .”

The fed­er­al gov­ern­men­t’s extreme focus on remde­sivir has been shaped, in large mea­sure, by the influ­ence of “Sci­en­tists to Stop COVID-19”:

1.–“Scientists to Stop Covid-19” is shep­herd­ing remde­sivir: ” . . . . Sci­en­tists to Stop COVID-19 rec­om­mends that in this phase, the U.S. Food and Drug Admin­is­tra­tion (FDA) should work to coor­di­nate with Gilead phar­ma­ceu­ti­cals to focus on expe­dit­ing the results of clin­i­cal tri­als of remde­sivir, a drug iden­ti­fied as a poten­tial treat­ment for COVID-19. The group also rec­om­mends admin­is­ter­ing dos­es of the drug to patients in an ear­ly stage of infec­tion, and notes remde­sivir will essen­tial­ly be a place­hold­er until a more effec­tive treat­ment is pro­duced.
2.–The group is doing so by atten­u­at­ing the reg­u­la­to­ry process for coro­n­avirus drugs: “Gov­ern­ment enti­ties and agen­cies appear to adhere to the rec­om­men­da­tions out­lined by the group, with the Jour­nal report­ing that the FDA and the Depart­ment of Vet­er­ans Affairs (VA) have imple­ment­ed some of the sug­ges­tions, name­ly relax­ing drug man­u­fac­tur­er reg­u­la­tions and require­ments for poten­tial coro­n­avirus treat­ment drugs. . . .”

We con­clude dis­cus­sion of the remde­sivir machi­na­tions with a piece about the tim­ing of the announce­ment of Grogan’s depar­ture.

” . . . . Gro­gan has served as the direc­tor of the White House Domes­tic Pol­i­cy Coun­cil since Feb­ru­ary 2019, over­see­ing a broad array of pol­i­cy issues includ­ing health care and reg­u­la­tion. . . . Gro­gan was one of the orig­i­nal mem­bers of the White House coro­n­avirus task force launched in late Jan­u­ary. . . . Gro­gan worked as a lob­by­ist for drug com­pa­ny Gilead Sci­ences before join­ing the Trump admin­is­tra­tion. . . .”

The depar­ture was announced in the Wall Street Jour­nal on the morn­ing of Wednes­day, April 29, the same day we got our first pub­lic reports of the NIAID clin­i­cal tri­al of remde­sivir that was pos­i­tive enough to show it short­ened the time to recov­ery and the same day the FDA grant­ed remde­sivir emer­gency use sta­tus. 

Note, again, the tim­ing of the DSM­B’s actions, as well as the influ­ence of “Sci­en­tists to Stop Covid-19.”

In FTR #1130, we not­ed that Mon­cef Slaoui–formerly in charge of prod­uct devel­op­ment for Moderna–was cho­sen to head Trump’s “Oper­a­tion Warp Speed.” He will be work­ing with Four-Star Gen­er­al Gus­tave Per­na, cho­sen by Chair­man of the Joint Chiefs of Staff Gen­er­al Mark Mil­ley.

Even after agree­ing to sell his Mod­er­na stock, Mon­cef Slaoui’s invest­ments raise alarm­ing questions–note that he is a “ven­ture cap­i­tal­ist” and a long­time for­mer exec­u­tive at Glaxo-Smithk­line:

The cir­cum­stances of his appoint­ment will per­mit him to avoid scruti­ny: ” . . . . In agree­ing to accept the posi­tion, Dr. Slaoui did not come on board as a gov­ern­ment employ­ee. Instead, he is on a con­tract, receiv­ing $1 for his ser­vice. That leaves him exempt from fed­er­al dis­clo­sure rules that would require him to list his out­side posi­tions, stock hold­ings and oth­er poten­tial con­flicts. And the con­tract posi­tion is not sub­ject to the same con­flict-of-inter­est laws and reg­u­la­tions that exec­u­tive branch employ­ees must fol­low. . . .”
He will retain a great deal of Glaxo-Smithk­line stock: ” . . . . He did not say how much his GSK shares were worth. When he left the com­pa­ny in 2017, he held about [500,000 in West­ern Print Edi­tion] 240,000 shares and share equiv­a­lents, accord­ing to the drug company’s annu­al report and an analy­sis by the exec­u­tive com­pen­sa­tion firm Equi­lar. . . .”
Fur­ther analy­sis of Slaoui’s posi­tion deep­ens con­cern about the integri­ty of the process: ” . . . . ‘This is basi­cal­ly absurd,’ said Vir­ginia Can­ter, who is chief ethics coun­sel for Cit­i­zens for Respon­si­bil­i­ty and Ethics in Wash­ing­ton. ‘It allows for no pub­lic scruti­ny of his con­flicts of inter­est.’ Ms. Can­ter also said fed­er­al law barred gov­ern­ment con­trac­tors from super­vis­ing gov­ern­ment employ­ees. . . . Ms. Can­ter, a for­mer ethics lawyer in the Oba­ma and Clin­ton admin­is­tra­tions, the Secu­ri­ties and Exchange Com­mis­sion and oth­er agen­cies, point­ed out that GSK’s vac­cine can­di­date with Sanofi could wind up com­pet­ing with oth­er man­u­fac­tur­ers vying for gov­ern­ment approval and sup­port. ‘If he retains stock in com­pa­nies that are invest­ing in the devel­op­ment of a vac­cine, and he’s involved in over­see­ing this process to select the safest vac­cine to com­bat Covid-19, regard­less of how won­der­ful a per­son he is, we can’t be con­fi­dent of the integri­ty of any process in which he is involved,’ Ms. Can­ter said.In addi­tion, his affil­i­a­tion with Medicxi could com­pli­cate mat­ters: Two of its investors are GSK and a divi­sion of John­son & John­son, which is also devel­op­ing a poten­tial vac­cine. . . .”

Next, we turn to Mod­er­na’s ani­mal tri­al for the mes­sen­ger RNA vac­cine it is devel­op­ing. There are sev­er­al con­sid­er­a­tions to be weighed in con­nec­tion with the Mod­er­na vac­cine.

1.–Again, the chair­man of Trump’s “Warp Speed” vac­cine devel­op­ment program–Moncef Slaoui–was in charge of Mod­er­na’s prod­uct devel­op­ment oper­a­tion.
2.–Moderna’s tri­al with mice was pos­i­tive with regard to gen­er­at­ing anti­body lev­els high enough to pre­vent ADE.
3.–Antibody Depen­dent Enhance­ment (ADE),  is a phe­nom­e­na where low lev­els of inef­fec­tive anti­bod­ies latch onto the virus and exac­er­bate an over­ac­tive immune response that leads to the dead­liest symp­toms likes cytokine-storms. This dan­ger was seen with SARS and attempts to cre­ate a SARS vac­cine so it’s a rea­son­able fear with SARS-CoV­‑2.
4.–The Phase III (human) tri­al is going to be start­ed in July, involv­ing 30,000 peo­ple. Alarm­ing­ly, those 30,000 peo­ple will all be receiv­ing the exact same dosage, 100 micro­grams, and that means the phase III tri­al won’t be test­ing sub-opti­mal dosages. The big Phase III tri­al won’t be test­ing for ADE in humans. 
5.–We may have a night­mare sit­u­a­tion where polit­i­cal pres­sure gives undo weight to ani­mal safe­ty results, leapfrog­ging over the neces­si­ty of test­ing for side effects. 
6.–The ani­mal tri­als have been severe­ly crit­i­cized: ” . . . . ‘This is the barest begin­ning of pre­lim­i­nary infor­ma­tion,’ said Dr. Gre­go­ry Poland, an immu­nol­o­gist and vac­cine researcher at the Mayo Clin­ic who has seen the paper, which has yet to under­go peer-review. Poland said the paper was incom­plete, dis­or­ga­nized and the num­bers of ani­mals test­ed were small. . . . Poland, who was not involved with the research, said the paper leaves out ‘impor­tant para­me­ters’ that could help sci­en­tists judge the work. . . .”
7.–We MIGHT cre­ate a vac­cine that pro­tects those who get a strong immune response while endan­ger­ing those with sub-pro­tec­tive responses–a “eugenic” vac­cine.
8.–The ani­mal tri­als have been severe­ly crit­i­cized: ” . . . . ‘This is the barest begin­ning of pre­lim­i­nary infor­ma­tion,’ said Dr. Gre­go­ry Poland, an immu­nol­o­gist and vac­cine researcher at the Mayo Clin­ic who has seen the paper, which has yet to under­go peer-review. Poland said the paper was incom­plete, dis­or­ga­nized and the num­bers of ani­mals test­ed were small. . . . Poland, who was not involved with the research, said the paper leaves out ‘impor­tant para­me­ters’ that could help sci­en­tists judge the work. . . .”
9.–The phase II clin­i­cal tri­als on humans are still under­way and won’t be com­plet­ed before Novem­ber.  Phase III is going to be get­ting under­way in July. The Human clin­i­cal tri­als are already under­way at the same time the ani­mal safe­ty tri­als have yet to be com­plet­ed.
10.–Side effects can take a while to man­i­fest.

We pro­vid­ed detailed crit­i­cal com­ments on Mod­er­na’s Phase I tri­al in FTR #1132.

We con­clude with a New York Times arti­cle sets forth a “Vac­cine Octo­ber Sur­prise” sce­nario for this fall.

” . . . . In a des­per­ate search for a boost, he could release a coro­n­avirus vac­cine that has not been shown to be safe and effec­tive as an Octo­ber sur­prise. Oct. 23, 2020, 9 a.m., with 10 days before the elec­tion, Fox New releas­es a poll show­ing Pres­i­dent Trump trail­ing Joe Biden by eight per­cent­age points. Oct. 23, 2020, 3 p.m., at a hasti­ly con­vened news con­fer­ence, Pres­i­dent Trump announces that the Food and Drug Admin­is­tra­tion has just issued an Emer­gency Use Autho­riza­tion for a coro­n­avirus vac­cine. Mr. Trump declares vic­to­ry over Covid-19, demands that all busi­ness­es reopen imme­di­ate­ly and pre­dicts a rapid eco­nom­ic recov­ery. Giv­en how this pres­i­dent has behaved, this incred­i­bly dan­ger­ous sce­nario is not far-fetched. In a des­per­ate search for a polit­i­cal boost, he could release a coro­n­avirus vac­cine before it had been thor­ough­ly test­ed and shown to be safe and effec­tive. . . .”

Custom Search

ESSENTIAL BACKGROUND

Martin BormannMartin Borman, Nazi in Exile by Paul Manning. German corporate capital flight program in the waning years of WWII.
Available for download. Read more about the Bormann Organizaton »